- Home
- IDYA vs MIRM Comparison
IDYA vs MIRM Comparison
Compare IDYA & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- MIRM
- Stock Information
- Founded
- IDYA 2015
- MIRM 2018
- Country
- IDYA United States
- MIRM United States
- Employees
- IDYA N/A
- MIRM N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- IDYA Health Care
- MIRM Health Care
- Exchange
- IDYA Nasdaq
- MIRM Nasdaq
- Market Cap
- IDYA 2.2B
- MIRM 2.1B
- IPO Year
- IDYA 2019
- MIRM 2019
- Fundamental
- Price
- IDYA $22.18
- MIRM $46.95
- Analyst Decision
- IDYA Strong Buy
- MIRM Strong Buy
- Analyst Count
- IDYA 13
- MIRM 11
- Target Price
- IDYA $53.67
- MIRM $57.00
- AVG Volume (30 Days)
- IDYA 890.0K
- MIRM 450.2K
- Earning Date
- IDYA 02-18-2025
- MIRM 02-26-2025
- Dividend Yield
- IDYA N/A
- MIRM N/A
- EPS Growth
- IDYA N/A
- MIRM N/A
- EPS
- IDYA N/A
- MIRM N/A
- Revenue
- IDYA $3,922,000.00
- MIRM $307,028,000.00
- Revenue This Year
- IDYA N/A
- MIRM $82.14
- Revenue Next Year
- IDYA $251.89
- MIRM $26.18
- P/E Ratio
- IDYA N/A
- MIRM N/A
- Revenue Growth
- IDYA N/A
- MIRM 112.14
- 52 Week Low
- IDYA $22.10
- MIRM $23.14
- 52 Week High
- IDYA $47.74
- MIRM $48.89
- Technical
- Relative Strength Index (RSI)
- IDYA 31.90
- MIRM 65.98
- Support Level
- IDYA $22.17
- MIRM $40.55
- Resistance Level
- IDYA $24.06
- MIRM $47.25
- Average True Range (ATR)
- IDYA 1.06
- MIRM 1.49
- MACD
- IDYA -0.22
- MIRM 0.56
- Stochastic Oscillator
- IDYA 1.84
- MIRM 95.52
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.